Full-Time

Director IT Quality

Compliance and Technology Assurance

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$185k - $220k/yr

+ Annual Bonus Program + 401(k) company match + Long Term Incentive Program

Princeton, NJ, USA

Hybrid

Hybrid work is indicated; the role requires up to 10% domestic and international travel.

Bachelor's

Category
Biology & Biotech (1)

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • A bachelor’s degree in Information Technology, Engineering, or Business is required.
  • A strong computer science background demonstrated through industry experience is required.
  • At least 15 years of experience in technology assurance, IT quality, validation, or related disciplines within regulated industries such as pharmaceuticals or life sciences is required.
  • Deep, demonstrable expertise in computer system validation, Computer Software Assurance, and risk-based assurance in regulated environments is required.
  • Strong understanding of global regulatory expectations, including FDA Computer Software Assurance guidance, GAMP, and EU Annex 11, and the ability to apply them pragmatically is required.
  • Proven ability to design assurance frameworks and governance models rather than only execute validation activities is required.
  • Strong grasp of modern IT delivery models, including commercial off-the-shelf systems, software as a service, cloud platforms, and configurable systems, is required.
  • The candidate must be recognized as a subject-matter authority with strong personal credibility.
  • The candidate must be comfortable operating with ambiguity and defining structure where none exists.
  • The candidate must lead through clarity, proportionate control, and trust rather than bureaucracy.
  • The candidate must be able to balance regulatory rigor with business pragmatism.
  • The candidate must demonstrate disciplined governance behavior, ensuring decisions and escalations follow the authority boundaries and thresholds defined in the CSA Governance Framework.
Responsibilities
  • Own and define the global technology assurance strategy spanning GxP and non-GxP systems.
  • Act as the enterprise authority on risk-based assurance, providing clear, defensible guidance to IT, Quality, and business leadership.
  • Ensure assurance decisions are evidence-based, proportionate, aligned with regulatory expectations, and consistent with organizational risk appetite.
  • Design, establish, and lead the Global Computer Software Assurance Centre of Excellence.
  • Define the Centre of Excellence mandate, operating model, RACI, and engagement model across global and regional teams.
  • Lead through authority and structure, enabling regional capability owners rather than centralized execution.
  • Ensure the Centre of Excellence operates within its defined authority, maintaining structural separation from delivery execution while providing oversight and interpretation support.
  • Establish and maintain the Computer Software Assurance framework, lifecycle, governance model, and standards as the accountable authority for methodology and interpretation within Operational Governance.
  • Define assurance decision points, artifact expectations, and inspection narratives that are consistent, scalable, and audit-ready.
  • Ensure alignment with global Quality, Audit, and Regulatory stakeholders while maintaining independence of technical judgment.
  • Escalate unresolved matters relating to methodology, interpretation, or cross-regional consistency to the Computer Software Assurance Steering Committee according to the Decision Authority and Risk Acceptance Model.
  • Enable sustainable Computer Software Assurance capability across regions through governance, coaching, and targeted enablement.
  • Oversee the development of Regional Computer Software Assurance Champions and ensure consistent application of Computer Software Assurance principles.
  • Reduce reliance on central assurance through clear frameworks and decision structures.
  • Define the long-term Computer Software Assurance maturity roadmap, including the role of tooling and automation.
  • Ensure tooling decisions are evidence-led and support a proven Computer Software Assurance operating model rather than drive it.
  • Sponsor targeted experimentation to inform future enterprise tooling standards.
  • Act as a trusted advisor to the Chief Information Officer, IT leadership team, Quality leadership, and the Computer Software Assurance Steering Committee.
  • Represent technology assurance in enterprise governance forums.
  • Provide clear, calm leadership in inspection, audit, and regulatory interactions.
Desired Qualifications
  • An advanced degree in Information Technology or Engineering is preferred.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for PreCheck on June 30, 2026, accelerating biologics launch readiness.
  • Crysvita expanded adult XLH dosing in May 2026, extending treatment uptake and persistence.
  • 2025 revenue reached ¥496.8 billion, and 2026 guidance rises to ¥520.0 billion.

What critics are saying

  • Crysvita sales still dominate; any reimbursement squeeze or safety issue hits 2026 results fast.
  • Sanford slips past 2027, and the FDA PreCheck advantage evaporates into delay and cost.
  • March 2026 leadership turnover, including CFO Motohiko Kawaguchi, disrupts execution and accountability.

What makes Kyowa Kirin unique

  • Crysvita remains the only approved XLH therapy, protecting a rare-disease franchise in 2026.
  • Sanford, North Carolina gives Kyowa Kirin a first U.S. biologics manufacturing base by 2027.
  • Benchling deployment in Tokyo and Fuji formalizes AI-enabled R&D workflows across discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.